Novartis AG (NYSE: NVS), a leading Swiss pharmaceutical company, last week announced positive preliminary data from a late-stage study for its complement inhibitor Fabhalta (iptacopan) in patients with the ultra-rare kidney disease C3 glomerulopathy (C3G). The study showed that compared to placebo, iptacopan achieved a 35.1% reduction in proteinuria and demonstrated a numerical improvement in kidney function after six months of treatment.
Fabhalta has exhibited a favorable safety profile thus far, and the trial is set to continue for another six months in an unblinded study format. Novartis plans to submit regulatory filings for this indication in the second half of 2024, while it also continues to explore the drug’s potential in other rare diseases.- Flcube.com
